Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Verastem (VSTM – Research Report) today and set a price target of $9.00.

In a report released today, Gregory Renza from RBC Capital reiterated a Buy rating on Verastem (VSTM – Research Report), with a price target of ...

BTIG Research has recently reiterated Verastem Inc (VSTM) stock to Buy rating, as announced on December 31, 2024, according to Finviz. Earlier, on September 30, 2024, Guggenheim had initiated the ...

The US Food and Drug Administration (FDA) has accepted for priority review the new drug application (NDA) for avutometinib to be used in combination with defactinib for the treatment of adults with ...

Verastem's promising therapy for LGSOC could position them as a commercial-stage company by 2025. Click here to find out why ...

An NDA has been accepted by the FDA for the combination of avutometinib and defactinib in KRAS-mutated recurrent low-grade ...

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) under Priority Review for avutometinib, in combination with defactinib, for the treatment of adults with ...

FDA officials have set a review date of June 30, 2025, to review avutometinib in combination with defactinib to treat ...

When compared to the broader market, Verastem Oncology has shown exceptional performance. The company’s stock has surged 30.57% year-to-date, a stark contrast to the S&P 500’s meager performance of -0 ...

Verastem, Inc. is on the verge of FDA approval for their combo therapy avutometinib-defactinib, targeting low-grade serous ...

The FDA accepts Verastem's NDA for the accelerated approval of avutometinib to treat recurrent KRAS mutant ovarian cancer under priority review. The stock rises 41%.

Highlights,FDA grants Priority Review for new treatment combination in recurrent KRAS mutant LGSOC.,Phase 2 trial results ...